0.9131USD+1.12%Mkt Cap: 25.33M USDP/E: —Last update: 2026-05-26
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap25.33M USD
Enterprise Value11.04M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-75.80M USD
Revenue/Share—
Last Price0.9131 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.47
PEG—
EV/EBITDA-0.16
EV/Revenue—
P/S—
P/B5.90
EPS (TTM)-2.58
EPS (Forward)-1.85
52W Range
0.62304% of range7.190
52W High7.190 USD
52W Low0.6230 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1826.09%
ROA-211.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.16M USD
CapEx (TTM)7.00K USD
FCF Margin—
FCF Yield-160.83%
Net Debt-13.39M USD
Net Debt/EBITDA0.19
Balance Sheet
Debt/Equity0.30
Current Ratio2.26
Quick Ratio1.57
Book Value/Sh0.1480 USD
Cash/Share0.5050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 4, 2024
Analyst Consensus
Rating2.3 (Buy)
Target (Mean)7.500 USD
Target Range1.500 USD – 20.00 USD
# Analysts5
Ownership
Shares Out.28.00M
Float21.88M
Insiders1.19%
Institutions60.57%
Short Interest
Short Ratio4.5d
Short % Float9.80%
Short % Out.9.71%
Shares Short2.72M
Short (prev mo.)3.02M
Technical
SMA 500.9624 (-5.1%)
SMA 2001.749 (-47.8%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)301.70K
Avg Vol (10d)218.91K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—